Invitation-Only VIP Dinner/ Hospitality Suite Sponsor will select invitees from the conference pre-registration list for an evening of networking at the hotel or a top local venue. CHI will extend invitations, conduct follow-up and monitor responses. Reminder cards will be placed in the badges of those delegates who will be attending.
Exclusive Cocktail Receptions
(Program-specific) CHI will invite all delegates from a specific conference program, of your choice, to your private reception at the host hotel. Cocktails and hors d'oeuvres will be served in a setting conducive to networking. These receptions are available on a first-come, first-served basis.
Other Promotional Opportunities:
• Conference Tote Bags
• Corporate Branding Packages
• Program Guide Event Directory Sponsorship
• Poster Award Sponsorship
• User-Group or Co-Locate Custom Events
• Tote Bag Inserts
• Networking Refreshment Breaks
• Poster Abstract Book
• Badge Lanyards Optimizing the design and use of non-clinical studies can reduce the uncertainty and increase the success of clinical trials. This talk will explore the use of relevant models, biomarkers, and PKPD to improve translations and, ultimately, allow better decisionmaking. various antibody-based therapeutic technologies are now available. a key to successful development of such drugs is using the right technology for specific targets. MedImmune's experience using different technologies to develop novel cancer antibody therapeutics will be described.
9:30 Sponsored Presentations
based therapies face several challenges. among them are the selection of patients most likely to benefit from clinical trials and lack of understanding of mechanisms of resistance to monoclonal antibody-based therapies. 
2:20 PD-1/PD-L1 Blockade Alan Korman, Ph.D., Vice President, Discovery Research, Bristol-Myers Squibb
We have developed human antibodies targeting Programmed Death-1 (PD-1) and its ligand PD-L1, a negative regulatory pathway that controls T-cell function. The activity of this pathway in murine models, non-human primates, and in-human clinical trials will be described.
2:50 Vaccination with Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
Carlos F. Santos, Ph.D., Senior Vice President, Clinical Development & Regulatory Affairs, Cancer Biologics, Biovest International, Inc. vaccination with patient-specific hybridoma-derived idiotype vaccine after chemotherapyinduced CR/ CRu may prolong disease-free survival in patients with follicular lymphoma. vaccine isotype may affect clinical outcome and explain differing results between this and other controlled Id-vaccine trials.
3:20 Close of Conference
Cambridge Healthtech Institute (CHI) appreciates your past participation at the Molecular Med TRI-CON. Through loyalty like yours, CHI has been able to build this event into a must attend for senior level decision-makers. as a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate. Just check off the box marked alumni Discount on the registration form to receive the discount! Please note: Our records must indicate you were an attendee of the Tri-Conference event in the past in order to qualify.
Receive 20% Off Your Registration!

Alumni Discount
Maximize Your Experience onsite at the Molecular Med Tri-Con!
The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people that you want to meet. This online system was designed with your privacy in mind and is only available to registered session attendees of this event. This talk will focus on items that have yet to be refined in routine implementation of genomic analysis in clinical care. It will discuss annotating genomic alterations of relevance to patients, matching patient genomic profiles to therapeutic profiles, and monitoring patients objectively.
11:40 DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non-Small Cell Lung Cancer
David S. Shames, Ph.D., Scientist, Development Oncology Diagnostics, Genentech, Inc. This presentation will discuss the discovery and development of DNa methylation biomarkers that are predictive of sensitivity to molecularly targeted agents such as erlotinib. I will also talk about promising new technology platforms that may be useful in the discovery of new biomarkers.
12:10 pm Methylation-Based Biomarkers for Predictive and Prognostic Use
Wim van Criekinge, Vice President, Science & Technology, MDx Health
MDxHealth's proprietary Methylation-Specific PCR (MSP) platform identifies DNa methylation-based oncology biomarkers for theranostic applications. a comprehensive epigenome-wide profiling pipeline has been established and will be discussed.
12:40 Luncheon Presentation I Multiplexing FFPE Samples in your Lab and Achieving Meaningful Results
Sponsored by
BJ Kerns, Senior Vice President, HTG Molecular
Learn how qNPa technology produces significant data from FFPe tissue with no extraction. Successfully quantitating multiple genes in a single well from FFPe differentiates qNPa technology from traditional gene expression methods. This presentation will review the clinical value of enumeration, introduce the most recent advancements in defining the molecular phenotype of CTCs, integrate this information for the prognosis and monitoring of response to therapy, and introduce their utility in pharmacodynamic monitoring.
1:10 Luncheon Presentation II Miniaturized Biomarker Assays in
Sponsored by
Complex Biological Samples for Drug Discovery and Clinical Trials
11:40 Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials for Predicting Benefit and Monitoring Patients Howard Scher, M.D., Chief, Genitourinary Oncology Service, Memorial SloanKettering Cancer Center
12:10 pm Clinical Significance of Circulating Tumor Cells in Breast Cancer
Minetta C. Liu, M.D., Associate Professor, Medical and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital
Prospective clinical trials demonstrate that the enumeration of circulating tumor cells (CTCs) has clinical utility when used in conjunction with radiographic imaging and clinical evaluations in the setting of metastatic breast cancer.
12:40 Molecular Analysis of Circulating Tumor Cells Using the IsoFlux System
Sponsored by
Carolyn Conant, Ph.D., Senior Scientist, Fluxion Biosciences
We discuss required attributes of CTC samples for downstream molecular diagnostics. The IsoFlux System is a novel platform that provides access to CTCs with high recovery, high purity, and low liquid volume. Clinical and analytical data will be shown that identifies sensitivity limits for genetic analyses using PCR and FISH approaches.
12:55 A Microfluidic System for the Selection of
Sponsored by
Circulating Tumor Cells that Utilizes both Affinity and Size Capture Technologies
Denis A. Smirnov, Director, On-Q-ity Inc.
Detection of rare circulating tumor cells (CTC) from blood promises to be valuable for diagnosis, prognosis and treatment of cancer patients. Current techniques, based solely on antibody affinity capture, are compromised by low capture efficiencies, presumably due to limited cell surface antigen expression. We will describe a novel CTC platform combining affinity capture with size filtration capture (C5 CTC chip). Utility of this system for enumeration and characterization of circulating cells will also be described. (Sponsorship Opp Avail) This presentation will discuss a polymer-based modular microfluidic system that can recover CTCs from whole blood, release the CTCs and then manipulate the CTCs into a containment reservoir using electrokinetics which can then be imaged for enumeration and genotyped at the single-cell level.
1:10 Luncheon Presentation
2:50 Isolation and Genotyping of Circulating Tumor Cells in a Miniaturized System
Chengxun Liu, Ph.D., Senior Researcher, Functional Nanosystems Group, imec This system integrates immunomagnetic isolation and genotyping for CTCs. The cell isolation module counts cells using a microelectronic sensor. Twenty specific genetic markers were reversely transcripted, amplified by multiplex ligation probe amplification and electrochemically detected in an automated miniaturized system.
3:20 Multi-Orifice Flow Fractionation (MOFF) for the Isolation and Characterization of Circulating Tumor Cells
Hyo-Il Jung, Ph.D. (Cantab), Associate Professor, School of Mechanical Engineering, Yonsei University
This talk will present a new microfluidic method for isolating circulating tumor cells (CTCs) through the combined use of inertial lift forces and turbulent secondary flows generated in a topographically patterned microchannel (MOFF, multi-orifice flow fractionation). 
KeynOTe PRESEntAtIon
8:00 Circulating and Disseminating Tumor Cells in Cancer Care
Stefanie Jeffrey, M.D., Chief, Surgical Oncology Research, Stanford University Applications for CTCs and DTCs in cancer management will be discussed, including different analytic approaches and strategies for personalized therapy.
8:30 CTC in the Neoadjuvant Setting: Why Do We Need More Information than Tumor PCR?
Jean-Yves Pierga, M.D., Medical Oncology, Institute Curie, Paris
Few studies have shown no correlation between pCR and CTC detection. CTC detection could be a valuable tool to predict relapse even in complete responders. Monitoring CTCs after tumor removal could be a surrogate marker for evaluating adjuvant treatment efficacy.
The simultaneous submission and approval of Pfizer's crizotinib and abbott Molecular's anaplastic lymphoma kinase (aLK) break-apart FISH companion diagnostic presented unique clinical and regulatory challenges, requiring novel approaches as well as close collaboration between Pfizer, abbott, CDeR, and CDRH.
9:30 Transforming Clinical Development with Adaptive Trials Oncology -A Case Study of an Oncology Registration Trial
Cryus Mehta, Ph.D., President and Co-Founder, Cytel Inc. Why are adaptive approaches on the rise in late phase oncology studies?
Over 50% of confirmatory studies end in failure -a distressing reality for cancer treatment developers and the medical community. In response, adaptive design strategies are helping reverse this discouraging trend. Using examples of ongoing adaptive trialsincluding the ongoing vaLOR trial a pivotal study for the treatment of acute Myeloid Leukemia, you'll learn: • the adaptations the FDa and eMa allow in both earlier and confirmatory stages • harnessing Conditional Power to effectively "de-risk" oncology development • to make the most of interim analysis with the validated • "Promising Zone" design strategy •
ethical considerations: what do participating patients gain in an adaptive study?
10:00 Transition to Plenary Keynote
PlENARy KEYNOTE
10:10 Plenary Keynote Presentation (See Page 3 for Details)
11:00 Refreshment Break in the Exhibit
Sponsored by
Hall with Poster Viewing
Oncology Clinical Trials 
ADDITIONAL REgISTRATION DETAILS
Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.
Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.
To view our Substitutions/Cancellations Policy, go to www.healthtech.com/regdetails
Video and or audio recording of any kind is prohibited onsite at all CHI events. • Your poster will be available to over 3,000 delegates
• Posters will be on display for two full days in the exhibit hall See bottom left for recommended pairings.
TRI-CON ALL ACCESS PACkAgE -Recommended Pairings
